Lung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. Non-small cell lung cancer is the most common variety accounting for 84% of the cases. For a subset of patients with actionable mutations, targeted therapy continues to provide durable responses. Advances in molecular and immunohistochemical techniques have made it possible to usher lung cancer into the era of personalized medicine, with the patient getting individualized treatment based on these markers. This review summarizes the recent advances in advanced NSCLC targeted therapy, focusing on first-in-human and early phase I/II clinical trials in patients with advanced disease. We have divided our discussion into different topics based on these agents' mechanisms of action. This article is aimed to be the most current review of available and upcoming targeted NSCLC treatment options. We will also summarize the currently available phase I/II clinical trial for NSCLC patients at the end of each section.

中文翻译：

---

晚期非小细胞肺癌的靶向治疗：当前进展和未来趋势

肺癌仍然是美国和全世界男性和女性癌症相关死亡的主要原因。非小细胞肺癌是最常见的类型，占病例的84%。对于一部分具有可操作突变的患者，靶向治疗继续提供持久的反应。分子和免疫组织化学技术的进步使肺癌进入个体化医疗时代成为可能，患者可以根据这些标志物获得个体化治疗。本综述总结了晚期 NSCLC 靶向治疗的最新进展，重点关注晚期疾病患者的首次人体和早期 I/II 期临床试验。我们根据这些药物的作用机制将讨论分为不同的主题。本文旨在对现有和即将推出的非小细胞肺癌靶向治疗方案进行最新综述。我们还将在每个部分的末尾总结目前针对 NSCLC 患者的 I/II 期临床试验。